You are here

Home » Content

Kronik Hemodiyaliz Hastalarında Hedef Hemoglobin Değerinin Sol Ventrikül Fonksiyonları Üzerine Etkisi

Effect of Target Hemoglobin Levels on Left Ventricle Functions in Chronic Hemodialysis Patients

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In patients with end stage renal disease (ESRD) the most important reason of increased mortality is cardiovascular disease. In these patients anemia is frequent and is shown to lead to left ventricle hypertrophy (LVH) and congestive heart failure. In this study, in order to evaluate the cardiac effects of target hemoglobin (Hb) values, we compared left ventricle (LV) functions of two groups of chronic hemodialysis patients, with normal and low Hb levels via echocardiogram. LV mass index (LVMI) and relative wall thickness (RWT) values indicated SVH, which is an independent factor for mortality and in the patient group with low Hb levels, these values were statistically significantly higher when compared with the group with normal Hb levels (p< 0.05 for LVMI and p< 0.05 for RWT). Furthermore, although the ejection fraction (EF) was within the normal limits in the group with low Hb levels, EF was statistically significantly lower when compared with the group with normal Hb levels (p<0.05). In our study, we observed that anemia plays a negative role on LVH and EF and we believe that if this anemia can be prevented, this will lead to a decrease in mortality.
Bookmark/Search this post with
Abstract (Original Language): 
Son dönem böbrek yetmezliği olan hastalarda artmış mortalitenin en önemli nedeni kardiyovasküler hastalıklardır. Bu hastalarda sıkça gelişen aneminin, sol ventrikül hipertrofisi (SVH) ve konjestif kalp yetmezliğine yol açtığı gösterilmiştir. Çalışmamızda, he¬ def hemoglobin (Hb) değerinin kardiyak etkilerini değerlendirmek üzere, Hb değeri normal ve düşük olan iki grup kronik hemodiyaliz hastasının SV fonksiyonlarını, ekokardiyografi ile değerlendirdik. Mortalite için bağımsız risk faktörü olan SVH'yi gösteren SV kitle indeksi (SVKİ) ve rölatif duvar kalınlığı değerleri (RDK); Hb değeri düşük olan grupta, Hb değeri normal olan gruba göre istatistiksel olarak anlamlı derecede yüksekti (SVKİ için p< 0.05, RDK için p< 0.05). Ayrıca ejeksiyon fraksiyonu (EF), Hb değeri düşük olan grupta nor¬ mal sınırlarda olmasına rağmen, Hb değeri normal olan grup ile karşılaştırıldığında istatistiksel olarak anlamlı şekilde daha düşüktü (p<0.05). Çalışmamızda aneminin hemodiyaliz hastalarında SVH ve EF üzerinde olumsuz etkileri olduğunu gözlemledik ve kardiyovasküler hastalık gelişmeden anemi önlenebilirse bunun mortalitede azalma ile sonuçlanacağını düşünmekteyiz.
FULL TEXT (PDF): 
PDF icon pdf_tndt_525.pdf
  • 2
80-84
  • Turkish

REFERENCES

References: 

1. Parfrey PS, Griffiths SM, Harnett JD, et al. Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients. Am J Nephrol 1990;10(3):213-221.
2. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent Left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354.
3. Silverberg DS, Wexler D, Blum M, et al. The use of subcuta¬neous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Car-diol 2000;35:1737-1744.
4. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin the¬rapy in predialysis patients with chronic renal failure. Am J
Kidney Dis 2000;35:250-256.
5. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state of knowledge. Kidney Int 2002;61(suppl 80):35-38.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.
7. O'Riordan E, Foley RN. Effects of anaemia on cardiovascular status. Nephrol Dial Transplant 2000;15(suppl 3):19-22.
8. Parfrey PS, Harnett JD, Griffiths SM, Gault MH, Barre PE.
Congestive heart failure in dialysis patients. Arch Intern Med 1988;148:1519-1525.
9. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Gutt-
mann RD. Left ventricular hypertrophy in end-stage renal
disease. Nephron 1988;48:107-115.
10. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre
PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11:1277-1285.
11. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal
disease. Kidney Int 1989;36:286-290.
12. Parfrey PS, Harnett JD, Griffiths SM, et al. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron
1990;55:114-120.
13. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocar-diographic disease in patients starting end-stage renal disease
therapy. Kidney Int 1995;47(1):186-192.
14. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Bar-
re PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis
1996;28:53-61.
15. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiom-
yopathy. Kidney Int 2000;58:1325-1335.
16. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and as¬sociated mortality in hemodialysis patients. J Am Soc Neph-rol 1999;10:610-619.
17. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int
1995 Mar;47(3):740-5.
18. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(2):1-47.

Thank you for copying data from http://www.arastirmax.com